Columbus-Based PreCelleon to License Cell Separation Technology Developed by OSU and Cleveland Clinic | TechColumbus

Columbus-Based PreCelleon to License Cell Separation Technology Developed by OSU and Cleveland Clinic

July 10, 2009

PreCelleon Inc. has agreed to license technology from Ohio State University and Cleveland Clinic to develop a tool that collects more cancerous cells for research and could potentially gauge the severity of cancer in a body.

The magnetic cell separation process is based on research from OSU’s Jeffrey Chalmers and Cleveland Clinic’s Maciej Zborowski. Cancerous cells can be tagged, separated and gathered for further study in a method that is more effective than current protocols. The tool can also tell how many circulating tumor cells are in a blood samples which can then guide researchers on best treatments for the patient.

“This new technology will give clinicians another piece of information they can use to more accurately predict the future and prescribe treatments,” says Tom Ward, president of PreCelleon.

The new technology will be incorporated in test equipment that will be built in Columbus.

For more details, see the story in MedCity News.